Table 1 Clinical and demographic characteristics of the analysis cohort (n = 573)
Covariables | |
|---|---|
Age at diagnosis (years) | 29.3 ± 11.9 |
Female sex, n (%) | 520 (91.3) |
Geographical origin, n (%) | |
Europe | 335 (58.5) |
Sub-Saharan Africa and West Indies (Antilles) | 99 (17.3) |
North Africa | 82 (14.3) |
Asia | 49 (8.6) |
Other | 8 (1.4) |
Total body weight (kg) | 64.9 ± 14.1 |
BMI (kg/m2) | 24.0 ± 4.8 |
Lean body mass (kg) | 41.5 ± 7.9 |
Active smoking, n (%) | 130 (22.7) |
Immunosuppressants, n (%) | |
Corticosteroids | 373 (65.1) |
Othera | 103 (18.0) |
SLEDAI score | 2.4 ± 3.2 |
Clinical manifestations | |
Photosensitivity | 328 (57.2) |
Malar rash | 276 (48.2) |
Discoid lupus | 64 (11.2) |
Arthritis | 506 (88.3) |
Oral ulcers | 96 (16.8) |
Haematological manifestations | 354 (61.8) |
Serositis | 146 (25.5) |
Nephropathy | 176 (30.7) |
Neuropsychiatric manifestations | 37 (6.5) |
HCQ daily dosing, n (%) | |
400 mg/day | 522 (91.1) |
200 mg/day | 51 (8.9) |
Biological characteristics | |
Leukocytes (× 109/l) | 6.3 ± 2.4 |
Neutrophils (× 109/l) | 4.4 ± 2.2 |
Lymphocytes (× 109/l) | 1. 5 ± 0.7 |
Platelets (× 109/l) | 253 ± 75 |
Haemoglobin (g/dL) | 13.1 ± 1.4 |
Creatinine clearance (mL/min) | 103 ± 32 |
Mild renal dysfunction†, n (%) | 224 (39.1) |
Moderate renal dysfunction‡, n (%) | 17 (3) |
Plasma C3 level (g/L) | 1.00 ± 0.23 |
Plasma C4 level (g/L) | 0.019 ± 0.08 |